Table 5 Association between the investigated genotypes and FVC% predicted in SSc patients in the discovery cohort

rs2736100 (T)^*

TERT

0.51 (-1.04; 2.05)

0.521

0.76 (-0.81; 2.34)

0.343

rs2076295 (G) ^*

DSP

−2.29 (-3.85; -0.74)

0.004

−2.52 (-4.09; -0.95)

0.002

rs4727443 (A)^*

AZGP1

−0.27 (-1.85; 1.32)

0.742

0.08 (-1.53; 1.70)

0.919

rs7934606 (A)^*

MUC2

−0.55 (-2.16; 1.05)

0.499

−0.75 (-2.37; 0.86)

0.360

rs2034650 (C)^*

IVD

0.67 (-0.90; 2.25)

0.402

0.37 (-1.22; 1.97)

0.646

rs1981997 (A) ^*

MAPT

2.26 (0.35; 4.17)

0.020

3.19 (1.23; 5.14)

0.001

rs12610495 (G)^*

DPP9

0.57 (-1.18; 2.32)

0.523

1.05 (-0.72; 2.82)

0.246

rs6793295 (C)^*

LRRC34

−0.46 (-2.19;1.27)

0.599

−1.05 (-2.82; 0.71)

0.242

rs2609255 (G)^*

FAMI3A

1.72 (-0.10; 3.55)

0.064

1.61 (-0.18; 3.41)

0.079

rs11191865 (G)^*

OBFC1

−0.73 (-2.27; 0.82)

0.356

0.02 (-1.55; 1.60)

0.977

rs1278769 (A)^*

ATP11A

−0.62 (-2.45; 1.20)

0.503

−0.74 (-2.60; 1.11)

0.433

rs1379326 (G)^†

CSMD1

3.35 (-0.84; 7.54)

0.117

3.12 (-1.08; 7.31)

0.145

rs17690703 (T) ^*

SPPL2C

2.04 (0.21; 3.88)

0.029

2.11 (0.30; 3.91)

0.022